Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

• Published in: Nature medicine Vol. 28; no. 11; pp. 2374 - 2380
• Main Authors: Gogishvili, Miranda, Melkadze, Tamar, Makharadze, Tamta, Giorgadze, Davit, Dvorkin, Mikhail, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Gessner, Christian, Moreno-Jaime, Brizio, Passalacqua, Rodolfo, Li, Siyu, McGuire, Kristina, Kaul, Manika, Paccaly, Anne, Quek, Ruben G. W., Gao, Bo, Seebach, Frank, Weinreich, David M., Yancopoulos, George D., Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.11.2022; Nature Publishing Group
• Subjects: 631/67/1059/2325; 631/67/1612/1350; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Apoptosis; B7-H1 Antigen - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Cell death; Chemotherapy; Disease-Free Survival; Double-Blind Method; Double-blind studies; Effectiveness; Empowerment; Histology; Humans; Immunotherapy; Infectious Diseases; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Metabolic Diseases; Molecular Medicine; Monoclonal antibodies; Neurosciences; Non-small cell lung carcinoma; Patients; PD-1 protein; PD-L1 protein; Placebos; Platinum; Platinum - therapeutic use; Protein-Tyrosine Kinases - therapeutic use; Proto-Oncogene Proteins; Small cell lung carcinoma; Survival; Targeted cancer therapy; Tumors
• ISSN: 1078-8956; 1546-170X
• DOI: 10.1038/s41591-022-01977-y

First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) and PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase 3 study, examined cemiplimab plus platinum-doublet chemotherapy as first-line treatment for aNSCLC, irrespective of PD-L1 expression or histology. In this study, 466 patients with stage III/IV aNSCLC without EGFR , ALK or ROS1 genomic tumor aberrations were randomized (2:1) to receive cemiplimab 350 mg ( n  = 312) or placebo ( n  = 154) every 3 weeks for up to 108 weeks in combination with four cycles of platinum-doublet chemotherapy (followed by pemetrexed maintenance as indicated). In total, 57.1% (266/466 patients) had non-squamous NSCLC, and 85.2% (397/466 patients) had stage IV disease. The primary endpoint was OS. The trial was stopped early per recommendation of the independent data monitoring committee, based on meeting preset OS efficacy criteria: median OS was 21.9 months (95% confidence interval (CI), 15.5–not evaluable) with cemiplimab plus chemotherapy versus 13.0 months (95% CI, 11.9–16.1) with placebo plus chemotherapy (hazard ratio (HR) = 0.71; 95% CI, 0.53–0.93; P  = 0.014). Grade ≥3 adverse events occurred with cemiplimab plus chemotherapy (43.6%, 136/312 patients) and placebo plus chemotherapy (31.4%, 48/153 patients). Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in aNSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies. Results from EMPOWER-Lung 3 demonstrate increased overall survival with cemiplimab plus platinum-doublet chemotherapy compared to cemiplimab as first-line treatment in patients with advanced non-small cell lung cancer, irrespective of PD-L1 expression.